Perry B. Molinoff
Chairman at MUSC Foundation for Research Development
Profile
Perry B.
Molinoff is currently the Chairman at MUSC Foundation for Research Development.
He is also a Director at Cita NeuroPharmaceuticals, Inc., Aegera Therapeutics, Inc., Cersci Therapeutics, Inc., and the University of Pennsylvania, where he holds the title of Professor-Emeritus.
In the past, Dr. Molinoff has worked as a Director at Cypress Bioscience, Inc. from 2004 to 2010, and as a Director at Palatin Technologies, Inc. from 2001 to 2011.
He also served as an Independent Non-Executive Director at Cynapsus Therapeutics, Inc. from 2012 to 2016, and as the Vice President-Development at Melior Discovery, Inc. Additionally, he held the position of VP-Neuroscience & Genitourinary Drug Discovery at Bristol-Myers Squibb Pharmaceutical Research Institute from 1995 to 2001.
Dr. Molinoff completed his undergraduate degree at Harvard University in 1962 and obtained his doctorate from Harvard Medical School in 1967.
Perry B. Molinoff active positions
| Companies | Position | Start |
|---|---|---|
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Director/Board Member | - |
Cita NeuroPharmaceuticals, Inc.
 Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Director/Board Member | - |
| University of Pennsylvania | Corporate Officer/Principal | - |
| MUSC Foundation for Research Development | Chairman | 2014-03-31 |
Cersci Therapeutics, Inc.
 Cersci Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cersci Therapeutics, Inc. operates as pharmaceutical company. The firm develops non-opioid analgesic drug products without the deleterious side effects. The company was founded by Lucas Rodriguez and Brent Duncan in 2019 and is headquartered in Dallas, TX. | Director/Board Member | - |
Former positions of Perry B. Molinoff
| Companies | Position | End |
|---|---|---|
| CYNAPSUS THERAPEUTICS INC | Director/Board Member | 2016-10-20 |
Cypress Bioscience, Inc.
 Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | Director/Board Member | 2009-12-31 |
| Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 2001-02-28 |
Melior Discovery, Inc.
 Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Director/Board Member | - |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Perry B. Molinoff
| Harvard University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PALATIN TECHNOLOGIES, INC. | Health Technology |
| Private companies | 8 |
|---|---|
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | Health Technology |
Cita NeuroPharmaceuticals, Inc.
Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Health Technology |
Cynapsus Therapeutics, Inc.
 Cynapsus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cynapsus Therapeutics, Inc. operated as a pharmaceutical company, which developed an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. The company was founded by Andrew Williams and David Hill on January 16, 2004 and was headquartered in Toronto, Canada. | Health Technology |
Melior Discovery, Inc.
Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Commercial Services |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Health Technology |
| MUSC Foundation for Research Development | |
| Bristol-Myers Squibb Pharmaceutical Research Institute | |
Cersci Therapeutics, Inc.
Cersci Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cersci Therapeutics, Inc. operates as pharmaceutical company. The firm develops non-opioid analgesic drug products without the deleterious side effects. The company was founded by Lucas Rodriguez and Brent Duncan in 2019 and is headquartered in Dallas, TX. | Health Technology |
- Stock Market
- Insiders
- Perry B. Molinoff